Paratek Pharmaceuticals Competitors, Revenue and Alternatives
Estimated Revenue & Financials
- Paratek Pharmaceuticals's estimated annual revenue is currently $17.1M per year.
- Paratek Pharmaceuticals received $50.0M in venture funding in January 2018.
- Paratek Pharmaceuticals's estimated revenue per employee is $92,027
- Paratek Pharmaceuticals's total funding is $133M.
- Paratek Pharmaceuticals has 186 Employees.
- Paratek Pharmaceuticals grew their employee count by 9% last year.
- Paratek Pharmaceuticals currently has 1 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|Vita Data Scien...||$8.4M||51||50%||N/A|
What Is Paratek Pharmaceuticals?
Paratek Pharmaceuticals (NASDAQ: PRTK) is a biopharmaceutical company that develops transformative solutions for patients, both in and out of the hospital, with diseases that are not responsive to current treatments. We focus on drugs that target infectious disease and other difficult to treat conditions. Our lead product candidate, omadacycline, is the first in a new class of tetracyclines known as aminomethycyclines, with broad spectrum activity against Gram-positive, Gram-negative and atypical bacteria. Omadacycline is being developed as a once daily, oral and intravenous, empiric monotherapy for community acquired bacterial infections, particularly when antibiotic resistance is of concern. The Food and Drug Administration (FDA) granted omadacycline a Qualified Infectious Disease Product (QIDP) designation and completed two special protocol assessments for its Phase 3 clinical trial program.keywords:Biotechnology,Healthcare,Mobile,Pharmaceuticals
Number of Employees
Employee Growth %
|Jeanne Jew||Senior VP, Business Development||Email Available|
|Susan Perkins||Vice President, Intellectual Property||Email Available|
|Vaughn Jennings||Regional Business Manager||Email Available|
|John McPartland||Director, Supply Chain||Email Available|
|Alexis Shaw||Senior Director, Compliance||Email Available|
|Christopher Bostrom||Senior Director of Finance||Email Available|
|Ben Strain||Executive Director, Investor Relations And Corporate Communications||Email Available|
|Sue Dear||Clinical Development And Medical Affairs Operations Manager||Email Available|
|Ron Jackson||Vice President, National Sales||Email Available|
|Mike Bowman||Regional Business Manager|
Paratek Pharmaceuticals News
BOSTON, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (PRTK), a commercial-stage biopharmaceutical company ...
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) stock has been on a recent steady downtrend, causing some concern for shareholders.
BOSTON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical ...
Paratek Pharmaceuticals Funding
|2008-04-17||$40.0M||Undisclosed||Aisling Capital, D.E. Shaw Group||Article|
Paratek Pharmaceuticals Executive Hires
|2002-08-13||Donna Supko||Dir Regulatory Affairs||Article|
|2003-02-13||Joseph Ianelli||VP Licensing||Article|
|2003-10-30||Sean M. Johnston||VP Manufacturing Ops||Article|
|2005-03-04||John P Dunphy||VP/CFO||Article|
|2014-07-02||Michael F. Bigham||Chairman/CEO||Article|
|2017-01-05||Evan Loh||President and Chief Operating Officer||Article|
Paratek Pharmaceuticals New Location/Offices
|2017-03-27||King of Prussia, PA||Article|
Paratek Pharmaceuticals Acquisitions
|2014-07-03||Transcept Pharmaceuticals, Inc||Article|
Paratek Pharmaceuticals Hiring Plans
|Date||Number of Employees||Location||Reference|